Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Fresh Tracks Therapeutics, Inc. (VICL)
|
Add to portfolio |
|
|
|
| Price: |
$0.92
| | Metrics |
| OS: |
5.91
|
M
| |
|
|
| Market cap: |
$5.42
|
M
| |
|
|
|
Net cash:
|
$8.95
|
M
| |
$1.51
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.4 | 1.8 | 7.9 | 10.9 | 13.8 | 14.5 | 21.0 | 15.2 |
| Revenue growth | -77.8% | -77.0% | -27.3% | -21.2% | -4.9% | -30.6% | 37.7% | 97.2% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 6.5 | 6.3 | 10.9 | 10.8 |
| Gross profit | 0.4 | 1.8 | 7.9 | 10.9 | 7.3 | 8.2 | 10.0 | 4.4 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 53.1% | 56.7% | 47.8% | 28.9% |
| Research and development | 28.2 | 11.2 | 20.2 | 13.0 | 14.4 | 10.4 | 11.1 | 11.5 |
| General and administrative | 12.4 | 11.6 | 12.2 | 6.4 | 6.3 | 7.1 | 8.4 | 9.6 |
| EBITA | -40.2 | -21.0 | -24.5 | -8.5 | -13.3 | -9.1 | -9.2 | -16.4 |
| EBITA margin | -9961.4% | -1151.3% | -309.1% | -77.6% | -96.1% | -62.5% | -43.9% | -107.9% |
| Amortization of intangibles | | | | | 0.1 | 0.1 | 0.2 | 0.2 |
| EBIT | -40.2 | -21.0 | -24.5 | -8.5 | -13.4 | -9.2 | -9.4 | -16.6 |
| EBIT margin | -9961.4% | -1151.3% | -309.1% | -77.6% | -96.9% | -63.2% | -44.9% | -109.3% |
| Pre-tax income | -39.5 | -20.9 | -23.9 | -9.2 | -13.0 | -9.0 | -9.2 | -16.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -39.5 | -20.9 | -13.6 | -15.2 | -13.0 | -9.0 | -9.2 | -16.5 |
| Net margin | -9777.2% | -1147.8% | -171.8% | -139.3% | -93.8% | -61.8% | -44.1% | -108.4% |
| |
| Diluted EPS | ($0.49) | ($0.85) | ($4.50) | ($25.85) | ($1.01) | ($0.90) | ($1.01) | ($1.86) |
| Shares outstanding (diluted) | 80.3 | 24.5 | 3.0 | 0.6 | 12.9 | 10.0 | 9.2 | 8.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|